According to the notice of the State Food and Drug Administration, it is believed that the Longshunrong Pharmaceutical Factory, which produced the Yinqiao Jie Tablets, "caused cross-contamination of drugs due to incomplete clearance in the process of drug production", and also pointed out that the incident was a "serious quality incident". At present, www.biquge.info the Food and Drug Administration has asked the Tianjin Municipal Market and Quality Supervision and Administration Commission to order "Longshunrong Pharmaceutical Factory to stop production and rectify and completely recall the products involved".

On April 22, Zhongxin Pharmaceutical was suspended again.

On April 18, the Hong Kong Department of Health reported that the sampling test found that the "Yinqiao Jiedu Tablets" produced by Tianjin Zhongxin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Zhongxin Pharmaceutical") Long Shunrong Pharmaceutical Factory contained trace amounts of paracetamol (the detected amount was 0.083mg/tablet).

However, the prescription approved by the State Food and Drug Administration for "Yinqiao Jie Tablets" does not contain paracetamol and should not be detected.

According to the State Food and Drug Administration, the Yinqiao Jie Tablets involved were drugs registered in Hong Kong by Long Shunrong Pharmaceutical Factory, and the products involved were produced in June 2014, with a total of 46 boxes.

The reason why Yinqiao Jiedu Tablets contain Western medicine ingredients this time is that Longshun Rong Pharmaceutical Factory also produces refined Yinqiao Jiedu Tablets, and the prescription of this product has been approved to contain paracetamol (60mg/tablet). According to an investigation by the State Food and Drug Administration, the Yinqiao Jiedu Tablets produced by Longshunrong Pharmaceutical Factory and the refined Yinqiao Jiedu Tablets shared a tablet press, which led to cross-contamination of the products due to incomplete clearance. At present, the same batch of stock products has been destroyed.

According to the State Food and Drug Administration, "the cross-contamination of drugs caused by incomplete clearance in the drug production process of Long Shunrong Pharmaceutical Factory is a serious quality incident that violates the Good Manufacturing Practice (hereinafter referred to as "Drug GMP"), reflecting the serious defects in the quality management of the enterprise." At present, the above-mentioned pharmaceutical factory has "stopped production for rectification and completely recalled the products involved".

Zhongxin Pharmaceutical Co., Ltd., a listed company, issued an announcement on the evening of April 20 to explain the incident, saying that "the investigation procedure has been immediately initiated", and revealed that in 2015, the variety was sold in Hong Kong, China for about 100,000 yuan, and has not yet received various complaints and adverse reaction reports. Zhongxin Pharmaceutical Co., Ltd. was suspended again on April 22 after April 20, and closed at 17.12 yuan on April 21, down 6.96% on the day.

The product involved in this case was not sold in Chinese mainland, but Yinqiao antidote tablets (Guoyao Z12020274) produced by the same pharmaceutical factory were also sold in Chinese mainland, and it is unknown whether the related products also shared tablet presses and cross-contamination. The State Food and Drug Administration said that it would later "file a case for investigation into illegal production behaviors such as drug GMP violations; Expand the sampling batches of the company's related products".

According to the notice of the State Food and Drug Administration, it is believed that the Longshunrong Pharmaceutical Factory, which produced the Yinqiao Jie Tablets, "caused cross-contamination of drugs due to incomplete clearance in the process of drug production", and also pointed out that the incident was a "serious quality incident". At present, the Food and Drug Administration has asked the Tianjin Municipal Market and Quality Supervision and Administration Commission to order "Long Shunrong Pharmaceutical Factory to suspend production for rectification and completely recall the products involved".

On April 22, Zhongxin Pharmaceutical was suspended again.

On April 18, the Hong Kong Department of Health reported that the sampling test found that the "Yinqiao Jiedu Tablets" produced by Tianjin Zhongxin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Zhongxin Pharmaceutical") Long Shunrong Pharmaceutical Factory contained trace amounts of paracetamol (the detected amount was 0.083mg/tablet).

However, the prescription approved by the State Food and Drug Administration for "Yinqiao Jie Tablets" does not contain paracetamol and should not be detected.

According to the State Food and Drug Administration, the Yinqiao Jie Tablets involved were drugs registered in Hong Kong by Long Shunrong Pharmaceutical Factory, and the products involved were produced in June 2014, with a total of 46 boxes.

The reason why Yinqiao Jiedu Tablets contain Western medicine ingredients this time is that Longshun Rong Pharmaceutical Factory also produces refined Yinqiao Jiedu Tablets, and the prescription of this product has been approved to contain paracetamol (60mg/tablet). According to an investigation by the State Food and Drug Administration, the Yinqiao Jiedu Tablets produced by Longshunrong Pharmaceutical Factory and the refined Yinqiao Jiedu Tablets shared a tablet press, which led to cross-contamination of the products due to incomplete clearance. At present, the same batch of stock products has been destroyed.

According to the State Food and Drug Administration, "the cross-contamination of drugs caused by incomplete clearance in the drug production process of Long Shunrong Pharmaceutical Factory is a serious quality incident that violates the Good Manufacturing Practice (hereinafter referred to as "Drug GMP"), reflecting the serious defects in the quality management of the enterprise." At present, the above-mentioned pharmaceutical factory has "stopped production for rectification and completely recalled the products involved".

Zhongxin Pharmaceutical Co., Ltd., a listed company, issued an announcement on the evening of April 20 to explain the incident, saying that "the investigation procedure has been immediately initiated", and revealed that in 2015, the variety was sold in Hong Kong, China for about 100,000 yuan, and has not yet received various complaints and adverse reaction reports. Zhongxin Pharmaceutical Co., Ltd. was suspended again on April 22 after April 20, and closed at 17.12 yuan on April 21, down 6.96% on the day.

The product involved in this case was not sold in Chinese mainland, but Yinqiao antidote tablets (Guoyao Z12020274) produced by the same pharmaceutical factory were also sold in Chinese mainland, and it is unknown whether the related products also shared tablet presses and cross-contamination. The State Food and Drug Administration said that it would later "file a case for investigation into illegal production behaviors such as drug GMP violations; Expand the sampling batches of the company's related products".

;